| Zacks Company Profile for Oncotelic Therapeutics, Inc. (OTLC : OTC) |
|
|
| |
| • Company Description |
| Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.
Number of Employees: 30 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.10 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 257,066 shares |
| Shares Outstanding: 439.09 (millions) |
| Market Capitalization: $42.99 (millions) |
| Beta: -0.68 |
| 52 Week High: $0.11 |
| 52 Week Low: $0.02 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
8.78% |
5.93% |
| 12 Week |
92.72% |
84.73% |
| Year To Date |
179.71% |
144.50% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
29397 AGOURA ROAD SUITE 107
-
AGOURA HILLS,CA 91301
USA |
ph: 650-635-7000
fax: 650-635-7001 |
ir@oncotelic.com |
http://www.oncotelic.com |
|
|
| |
| • General Corporate Information |
Officers
Vuong Trieu - Chairman and Chief Executive Officer
Amit Shah - Chief Financial Officer
Steven King - Director
Anthony Maida - Director
Steven W. King - Director and Consultant
|
|
Peer Information
Oncotelic Therapeutics, Inc. (CORR.)
Oncotelic Therapeutics, Inc. (RSPI)
Oncotelic Therapeutics, Inc. (CGXP)
Oncotelic Therapeutics, Inc. (BGEN)
Oncotelic Therapeutics, Inc. (GTBP)
Oncotelic Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 628341109
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/18/25
|
|
Share - Related Items
Shares Outstanding: 439.09
Most Recent Split Date: 12.00 (0.08:1)
Beta: -0.68
Market Capitalization: $42.99 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/18/25 |
|
|
|
| |
